Parkman Healthcare Partners LLC Takes $2.74 Million Position in Artivion, Inc. $AORT

Key Points

• Parkman Healthcare Partners LLC acquired a new stake in Artivion, Inc., buying 111,652 shares valued at approximately $2.74 million, representing about 0.26% ownership in the company.
• Insider trading activity included John E. Davis selling 10,802 shares for over $471,000, and Jean F. Holloway selling 23,356 shares for approximately $1 million, indicating a decrease in their ownership positions.
• Artivion recently reported $0.24 earnings per share for the quarter, exceeding expectations, with revenues of $112.97 million, a 15.3% increase year-over-year.

Parkman Healthcare Partners LLC bought a new stake in shares of Artivion, Inc. (NYSE:AORT - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 111,652 shares of the company's stock, valued at approximately $2,744,000. Parkman Healthcare Partners LLC owned about 0.26% of Artivion as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Illinois Municipal Retirement Fund grew its position in shares of Artivion by 3.1% during the 1st quarter. Illinois Municipal Retirement Fund now owns 20,519 shares of the company's stock valued at $504,000 after acquiring an additional 611 shares during the period. MCF Advisors LLC lifted its stake in Artivion by 109.3% in the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock worth $29,000 after purchasing an additional 614 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Artivion by 3.3% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,559 shares of the company's stock worth $645,000 after purchasing an additional 727 shares in the last quarter. Legacy Advisors LLC purchased a new stake in shares of Artivion during the 1st quarter valued at about $28,000. Finally, Natixis Advisors LLC raised its position in shares of Artivion by 16.4% during the 1st quarter. Natixis Advisors LLC now owns 12,615 shares of the company's stock valued at $310,000 after buying an additional 1,777 shares in the last quarter. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider John E. Davis sold 10,802 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $43.67, for a total transaction of $471,723.34. Following the sale, the insider directly owned 208,778 shares of the company's stock, valued at $9,117,335.26. This represents a 4.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Jean F. Holloway sold 23,356 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $43.01, for a total transaction of $1,004,541.56. Following the sale, the senior vice president directly owned 172,129 shares in the company, valued at approximately $7,403,268.29. The trade was a 11.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 115,990 shares of company stock valued at $4,435,823. Company insiders own 7.60% of the company's stock.

Artivion Stock Performance

AORT opened at $43.42 on Friday. The firm has a market capitalization of $2.05 billion, a PE ratio of -103.39 and a beta of 1.70. Artivion, Inc. has a twelve month low of $21.97 and a twelve month high of $45.07. The firm's 50-day moving average price is $36.34 and its 200 day moving average price is $29.78. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.13. The firm had revenue of $112.97 million for the quarter, compared to analyst estimates of $107.96 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. Artivion's revenue was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on AORT. JMP Securities upped their target price on shares of Artivion from $33.00 to $42.00 and gave the stock a "market outperform" rating in a research note on Friday, August 8th. Needham & Company LLC raised their target price on shares of Artivion from $45.00 to $50.00 and gave the company a "buy" rating in a research note on Friday, August 22nd. Oppenheimer reaffirmed an "outperform" rating on shares of Artivion in a report on Friday, August 8th. Stifel Nicolaus raised their target price on shares of Artivion from $36.00 to $40.00 and gave the stock a "buy" rating in a report on Friday, August 8th. Finally, LADENBURG THALM/SH SH cut shares of Artivion from a "buy" rating to a "neutral" rating and lifted their price objective for the company from $32.00 to $38.80 in a report on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $40.63.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

Want to see what other hedge funds are holding AORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Artivion, Inc. (NYSE:AORT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.